Content about tobramycin

March 25, 2013

FDA approves Novartis antibacterial treatment for cystic fibrosis

The Food and Drug Administration has approved a treatment for managing a type of bacterial infection in patients with cystic fibrosis.

EAST HANOVER, N.J. — The Food and Drug Administration has approved a treatment for managing a type of bacterial infection in patients with cystic fibrosis.

Swiss drug maker Novartis announced the approval of Tobi Podhaler (tobramycin inhalation powder) for managing cystic fibrosis patients with Pseudomonas aeruginosa, or Pa bacteria, in the lungs.

September 6, 2012

FDA advisory committee recommends approval for Novartis cystic fibrosis drug

A panel of Food and Drug Administration experts is recommending that the agency approve an experimental drug for cystic fibrosis made by Novartis, the Swiss drug maker said.

EAST HANOVER, N.J. — A panel of Food and Drug Administration experts is recommending that the agency approve an experimental drug for cystic fibrosis made by Novartis, the Swiss drug maker said.

September 22, 2010

Alcon's TobraDex ST treats inflammatory eye conditions

Eyecare company Alcon has launched a new drug for inflammatory eye conditions....

HUENENBERG, Switzerland Eyecare company Alcon has launched a new drug for inflammatory eye conditions.

Alcon announced the launch of TobraDex ST (tobramycin, dexamethasone ophthalmic suspension) in the 0.3%/0.5% strength. The drug is used to treat inflammatory eye conditions treatable with corticosteroids and where bacterial infection or risk of infection exists.